IL1B and myocardial infarction: The astonishingly reduction of incident lung cancer cases among patients with prior myocardial infarction treated with the anti-IL-1b antibody (canakinumab) in lung cancer [60] are indeed opening a new scenario for the crucial role of the IL-1 cytokine in cancer development.